Calliditas Therapeutics AB, announced that the global open-label extension study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration and estimated glomerular filtration rate at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd study.
